Loading stock data…
Viking Therapeutics, Inc. (VKTX)
$33.68-1.19 (-3.41%)
Market ClosedLast close Sep 8
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viking Therapeutics, Inc. in the Healthcare sector is trading at $33.68 with a market capitalization of $4.0B. Wall Street consensus targets $92.39 (19 analysts), implying a +174.3% move over the next 12 months. The stock is currently 22% below its 52-week high of $43.15, remaining 0.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +174.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$132.60M↑ | -$164.13M↑ | -$164.74M↓ | -$98.56M↓ | -$74.57M |
| Net Income | -$128.02M↑ | -$158.32M↓ | -$157.66M↓ | -$90.79M↓ | -$65.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-130.98%
Volume
Today's trading volume
1.86M
Recent News
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.
Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?
Viking Therapeutics stock has delivered a very strong 5 year run, yet current valuation checks suggest the shares are priced at the richer end of the spectrum rather than as a clear bargain. Around 411.0% total return over 5 years highlights how much optimism has already been reflected in Viking Therapeutics shares. Progress of obesity candidate VK2735 and other metabolic programs, supported by a reported US$502 million cash position, can support high expectations, while any setback in...
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day.
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
Viking Therapeutics deserves a second look, but some analysts are a bit too optimistic.